Skip to content

US · ANAB · BIOTECHNOLOGY

AnaptysBio, Inc. (ANAB) intrinsic value and stock valuation

$46.63as of 2026-11-21 · Mkt cap 2.37B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AnaptysBio, Inc. DCF and intrinsic value

InvestorsCraft values ANAB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ANAB’s statements →

AnaptysBio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121-5801 anaptysbio.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$234.6M+25.6% 5y CAGRd
20132025
Net income
-$-13.23M
20132025
Free cash flow
$19.6M
20132025
Total equity
$37.2M-37.7% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$234.6M$91.3M$17.2M$10.3M$63.2M
Operating income$47.9M-$-114.95M-$-164.41M-$-115.15M-$-56.81M
Net income-$-13.23M-$-145.23M-$-163.62M-$-128.72M-$-57.8M
EPSd-$-422.14K-$-5.12M-$-6.08M-$-4.57M-$-2.11M
Operating cash flow$19.7M-$-135.34M-$-120.8M-$-73.59M-$-45.92M
Capital expenditure-$-90K-$-360K-$-810K-$-360K-$-1.37M
Free cash flow$19.6M-$-135.69M-$-121.61M-$-73.95M-$-47.29M
Total assets$364.4M$483.8M$452.4M$610.4M$643.1M
Total debt$14.1M$369.5M$17.8M$19.5M$21M
Net debt-$-224.08M$246.4M-$-18.15M-$-51.86M-$-474.77M
Total equity$37.2M$70.9M$88.1M$262.1M$356.4M
Cash and short-term investments$311.6M$385.4M$390.9M$441.2M$548.1M
Income statement
20252024202320222021
Revenue$234.6M$91.3M$17.2M$10.3M$63.2M
Cost of revenue$2.42M$163.8M$132.3M$88.8M$98.5M
Gross profit$232.2M-$-72.56M-$-115.13M-$-78.51M-$-35.32M
Research and development expenses$136M$163.8M$139.6M$88.8M$98.5M
Selling, general and administrative expenses$50.7M$42.4M$42M$36.6M$21.5M
Other expenses-$-2.42M-$-163.84M-$-132.28M-$-88.8M-$-98.5M
Operating expenses$184.3M$42.4M$49.3M$36.6M$21.5M
Cost and expenses$186.7M$206.2M$181.6M$125.4M$120M
Interest income$13.5M$19.8M$18.9M$7.55M$430K
Interest expense$79.9M$50.1M$18.1M$21.1M$1.45M
Depreciation and amortization$2.42M$2.4M$650K$2.33M$2.09M
Ebitda$69.3M-$-92.74M-$-156.42M-$-105.26M-$-55.71M
Operating income$47.9M-$-114.95M-$-164.41M-$-115.15M-$-56.81M
Total other income/expenses, net-$-60.96M-$-30.28M$790K-$-13.55M-$-980K
Income before tax-$-13.07M-$-145.23M-$-163.62M-$-128.7M-$-57.8M
Income tax expense$160K$0.00-$0.00$20K$0.00
Net income-$-13.23M-$-145.23M-$-163.62M-$-128.72M-$-57.8M
Weighted average shares outstanding$27.8M$28.4M$26.9M$28.2M$27.4M
Weighted average diluted shares outstanding$31.3M$28.4M$26.9M$28.2M$27.4M
Balance sheet
20252024202320222021
Cash and short-term investments$311.6M$385.4M$390.9M$441.2M$548.1M
Net receivables$33.9M$40.8M$6.85M$1.42M$880K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$350.3M$431.9M$406.8M$447.2M$553.9M
Property, plant and equipment, net$13.9M$16.2M$18.3M$20M$21.8M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$35.5M$27M$142.9M$67.1M
Total non-current assets$14.1M$52M$45.6M$163.2M$89.2M
Total assets$364.4M$483.8M$452.4M$610.4M$643.1M
Accounts payable$3.87M$4M$4.7M$2.78M$1.74M
Short-term debt$2.08M$1.93M$1.78M$1.64M$1.5M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$38.6M$45.4M$37.4M$26.1M$16.1M
Long-term debt$12M$367.5M$16M$17.8M$19.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$288.6M$367.5M$326.8M$322.2M$270.5M
Capital lease obligations$2.08M$14.1M$17.8M$19.5M$21M
Total liabilities$327.2M$413M$364.3M$348.3M$286.6M
Common stock$30K$30K$30K$30K$30K
Retained earnings-$-772.56M-$-759.33M-$-614.1M-$-450.48M-$-321.75M
Accumulated other comprehensive income (loss)-$-20K$300K-$-800K-$-5.25M-$-420K
Total equity$37.2M$70.9M$88.1M$262.1M$356.4M
Total investments$73.4M$297.8M$382M$512.9M$119.5M
Total debt$14.1M$369.5M$17.8M$19.5M$21M
Net debt-$-224.08M$246.4M-$-18.15M-$-51.86M-$-474.77M
Cash flow statement
20252024202320222021
Net income$49.6M-$-145.23M-$-163.62M-$-128.72M-$-57.8M
Depreciation and amortization$2.42M$2.4M$2.38M$2.33M$2.09M
Stock-based compensation$36.1M$34.1M$33.2M$27.4M$15.4M
Change in working capital-$-80.72M-$-66.33M-$-320K$6.84M-$-7.49M
Accounts receivable$6.92M-$-33.91M-$-5.43M-$-540K-$-880K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-87.33M-$-33.84M$10.9M$9.7M-$-4.74M
Net cash provided by operating activities$19.7M-$-135.34M-$-120.8M-$-73.59M-$-45.92M
Investments in property, plant and equipment-$-90K-$-360K-$-810K-$-360K-$-1.37M
Acquisitions, net$0.00$0.00$0.00$394.5M$0.00
Net cash used for investing activities$228M$95.4M$144.8M-$-394.85M$38.8M
Common stock issued$14.3M$100.8M$2.47M$11.8M$2.55M
Common stock repurchased-$-68.63M-$-460K-$-50M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-132.61M$127.1M-$-59.3M$44M$252.3M
Net change in cash$115.1M$87.1M-$-35.34M-$-424.42M$245.2M
Cash at end of period$238.2M$123.1M$36M$71.3M$495.7M
Operating cash flow$19.7M-$-135.34M-$-120.8M-$-73.59M-$-45.92M
Capital expenditure-$-90K-$-360K-$-810K-$-360K-$-1.37M
Free cash flow$19.6M-$-135.69M-$-121.61M-$-73.95M-$-47.29M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AnaptysBio, Inc.

        AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

        CEO
        Daniel Faga
        Employees
        104
        Beta
        0.40

        Explore

        Frequently asked questions

        What is the intrinsic value of AnaptysBio, Inc. (ANAB)?

        AnaptysBio, Inc. (ANAB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ANAB undervalued?

        ANAB trades at a price of $46.63 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.